Merck Pays $400 Million for Cancer Treatment Rights Amid Patent Expiration Looming
Pharmaceutical giant Merck has taken a big step in its quest to develop new cancer treatments by acquiring rights to a promising drug candidate from SciBrunch Therapeutics. The deal, worth $400 million upfront, gives Merck exclusive worldwide rights to SPR2015, an oral KRAS G12D inhibitor that has yet to reach human testing.
The valuation of the deal is significant, with a headline value of $2.13 billion, although this amount depends on future milestones and could be worth as little as $1.73 billion if those goals are not met. This upfront payment may seem steep, but it's a necessary investment for Merck as it prepares to face patent expirations on its popular Keytruda treatment later this decade.
The acquisition is seen as a way for Merck to stay ahead of the competition and maintain its position in the market. However, investors are already paying a premium for Merck's shares, which sit 21.21% above their estimated value of $120.85 per share. This raises concerns that the company may be overpaying for the rights to SPR2015.